SCHEMBL1458796

SCHEMBL1458796

CCn1nc(-c2ccncc2)cc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 3/20 0.34
▸ MAPT P10636 2/20 0.33
▸ PTGS2 P35354 2/20 0.32
▸ S1PR1 P21453 1/20 0.32
▸ CDC7 O00311 1/20 0.32
▸ PKN1 Q16512 1/20 0.32
▸ PKN2 Q16513 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459537 0.90 SMN1; SMN2 (0.40) MAPTPTGS2S1PR1POLBSMN1; SMN2
SCHEMBL1458892 0.87 CYP2A6 (0.43) PTGS2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1459533 0.83 GSK3B (0.36) GSK3BMAPTPTGS2CDC7ALDH1A1
SCHEMBL1459578 0.81 PTGS2 (0.46) PTGS2POLBKDM4E
SCHEMBL1460033 0.81 KLK3 (0.32) KDM4EALDH1A1HPGDTSHR
SCHEMBL1460054 0.76 TGFBR1 (0.39) POLBKDM4EALDH1A1TSHRTP53
SCHEMBL1459530 0.75 SMN1; SMN2 (0.45) MAPTPTGS2POLBSMN1; SMN2ALDH1A1
SCHEMBL14844251 0.71 CYP2A6 (0.47) MAPTPTGS2KDM4EALDH1A1HPGD
SCHEMBL1459841 0.70 CYP2A6 (0.42) PTGS2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1257313 0.69 PTGS2 (0.38) PTGS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 — — EP disclosed
CN-102574788-A Indole derivatives as crac modulators HOFFMANN LA ROCHE 2012-07-11 — — CN disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E GSK3B 1343/4885MAPT 2068/4885PTGS2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback